ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate Updates tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
ProKidney (PROK) Reports Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
ProKidney confirms Winston-Salem expansion plan, add 50 jobs journalnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journalnow.com Daily Mail and Mail on Sunday newspapers.
ProKidney confirms Winston-Salem expansion plans journalnow.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from journalnow.com Daily Mail and Mail on Sunday newspapers.
05.09.2023 - WINSTON-SALEM, N.C., Sept. 05, 2023 (GLOBE NEWSWIRE) - ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from . Seite 1